Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]
Discontinued
Reference number: GID-TA10590
The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]
The company have advised that they will not be seeking regulatory approval for nivolumab for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme.
As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if or when the situation changes.